Monday, July 9

0800-1600 REGISTRATION

0900-1700 ANAEROBIC IDENTIFICATION AND SUSCEPTIBILITY — See page 3 for details
  Diane M. Citron
  Mike Cox

0900-1700 EXAMINING ANAEROBES IN THE MICROBIOME: METAGENOMIC AND CULTURE APPROACHES — See page 3 for details
  Laura M. Cox, Ph.D.
  Anna Seekatz, Ph.D.
  Casey Theriot, Ph.D.

1800 ASA BOARD DINNER/MEETING

1800 BREWS, WINE & WINGS
  ROBERT IRVINE’S PUBLIC HOUSE, TROPICANA

Tuesday, July 10

0700-0820 REGISTRATION / BREAKFAST / EXHIBITS

0820-0830 WELCOME
  Jeanne Marrazzo, M.D.

0830-0945 SESSION I: ONE HEALTH: SYNERGY BETWEEN HUMAN & ANIMAL ECOCLOGIC SYSTEMS
  Convener: Francisco Uzal, Ph.D.
  Pathogenesis of C. perfringens Type C Infections in Humans and Animals
  Jibong Li, Ph.D.
  University of Pittsburgh, Pittsburgh, PA USA
  Pathobiology of Clostridial Hepatitis in Animals
  University of California, Davis, Davis, CA USA
  Brachyspira spp. Infections in Animals and Humans
  Eric R. Burrough, D.V.M., Ph.D.
  Iowa State University, Ames, IA USA

0945-1000 BREAK / INDUSTRY EXHIBITS

1000-1100 SESSION II: KEYNOTE PRESENTATION
  Convener: Jeanne Marrazzo, M.D.
  Microbiota and the Brain–Gut Axis
  Sarkas Mazmanian, Ph.D.
  California Institute of Technology, Pasadena, CA USA

1100-1200 SESSION III: ANAEROBIC CLINICAL ISSUES IN HUMAN DISEASE
  Convener: Ellie Goldstein, M.D.
  The Role of Anaerobes in Pneumonia: A Breath of Fresh Air
  Stephen G. Jenkins, Ph.D.
  Weill Cornell Medicine, New York, NY USA
  Propionibacterium acnes and Shoulder Surgery
  Paul G. Auwaerter, M.D.
  Johns Hopkins University, Baltimore, MD USA
  Characterization of Cutibacterium (ex. Propionibacterium) acnes Populations in Patients with Acne versus Healthy Skin: Interest of a Local Adjunctive Therapy Based on Myrtacine
  Christine G. Roques, Ph.D.
  Université Paul Sabatier, Toulouse, France

1200-1320 LUNCH / INDUSTRY EXHIBITS / STUDENT POSTERS

1320-1415 SESSION IV: SYSTEMS BIOLOGY TO STUDY THE MICROBIOME & INFECTIOUS DISEASES
  Convener: Casey Theriot, Ph.D.
  Extracting Actionable Knowledge from the EHR: Machine Learning Tools for Predicting Risk of CDI
  Jenna Wiens, Ph.D.
  University of Michigan, Ann Arbor, MI USA
  Mathematical Modeling of C. difficile Infection and Antimicrobial Resistance
  Cristina Lanzas, D.V.M., Ph.D.
  North Carolina State University, Raleigh, NC USA

1415-1510 SESSION V: NEW TOPICS IN ANAEROBIC SCIENCE
  Convener: Yiping Han, Ph.D.
  C. difficile Phage
  Martha R.J. Clokie, Ph.D.
  University of Leicester, Leicester, United Kingdom
  Engineering Regulatory Systems to Modulate Gene Expression of Bacteroides in the Gut
  Bentley Lim, Ph.D.
  Yale University, New Haven, CT USA

1510-1530 BREAK / INDUSTRY EXHIBITS

1530-1645 SESSION VI: GENITAL TRACT ANAEROBES, HIV/STI ACQUISITION & REPRODUCTIVE HEALTH
  Convener: David Fredricks, M.D.
  Microbiome Studies to Define the Role of Vaginal Anaerobes in Increasing Susceptibility to HIV
  Sujatha Srinivasan, Ph.D.
  Fred Hutchinson Cancer Research Center, Seattle, WA USA
  The Role of Vaginal Anaerobes in HIV: New Data & Proposed Mechanisms
  Douglas S. Kwon, M.D., Ph.D.
  Harvard Medical School, Cambridge, MA USA
  Anaerobes & Immunity in the Genital Tract
  Caroline M. Mitchell, M.D.
  Massachusetts General Hospital, Boston, MA USA

1645-1800 SESSION VII: ORAL PRESENTATIONS I—INTERNATIONAL PERSPECTIVES
  Convener: Daniel Paredes-Sabja, Ph.D.
  Ongoing Research on Anaerobes in Europe
  Elisabeth Nagy, Ph.D.
  University of Szeged, Szeged, Hungary
  UK Bacteroides Species Surveillance Survey: Change in Antimicrobial Resistance Over 16 Years
  Harriet C. Hughes, Ph.D.
  UK Anaerobe Reference Unit, Cardiff, United Kingdom
  Clostridioides difficile: What Do We Know about this Pathogen in Brazil?
  Eliane O. Ferreira, Ph.D.
  Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil

1800 WINE & CHEESE RECEPTION
Wednesday, July 11

0700-0745 REGISTRATION / BREAKFAST / EXHIBITS
0745-0845 SESSION VIII: ORAL PRESENTATIONS II—SEQUENCING & PROBIOTICS
  Convener: Ernesto Abel-Santos, Ph.D.
  Challenges of Next-Generation-Sequencing Targeting Anaerobes
    Georg Conrad, Ph.D.
    Aachen University Hospital, Aachen, Germany
  Phylogenomic Analysis of Fusobacterium Necrophorum Based on Whole Genome Sequencing and Its Association with Disease and Host
    Anders A. Jensen, Ph.D.
    Aarhus University, Aarhus, Denmark
  Lactobacillus Cocktails Modulate Monocyte Immune Responses to Pathogenic Vaginal Anaerobes
    Hidemi Yamamoto
    Harvard Medical School, Cambridge, MA USA
  Clostridium difficile Virulence Factors Impaired by BIO-K+ Probiotics
    Sathurcha Gunaratnam
    INRS-Institut Armand-Frappier, Laval, Canada

0845-0900 BREAK / INDUSTRY EXHIBITS
0900-1020 SESSION IX: THE ORAL MICROBIOME & HUMAN HEALTH
  Convener: Purnima Kumar, D.D.S.
  P. gingivalis as an Orchestrator of Dysbiosis in Periodontitis
    George Hajishengallis, D.D.S., Ph.D.
    University of Pennsylvania, Philadelphia, PA USA
  Iron Utilization in Enhancing Virulence Potential of Oral Anaerobes
    Janina Lewis, Ph.D.
    Virginia Commonwealth University, Richmond, VA USA
  SyngenicDNA: Making Every Bacterial Species Genetically Tractable
    Christopher D. Johnston, Ph.D.
    The Forsyth Institute, Cambridge, MA USA
  Nitrosative Stress Sensing in Porphyromonas gingivalis: Structure and Function of the Heme Binding Transcriptional Regulator HCPR
    Benjamin Ross Belvin
    Virginia Commonwealth University, Richmond, VA USA

1020-1045 BREAK / INDUSTRY EXHIBITS
1045-1200 SESSION X: FUSOBACTERIUM AND PATHOGENESIS
  Convener: Sarah Kuebne, Ph.D.
  New Insights into Fusobacterium-Associated Colorectal Cancers
    Susan Bullman, Ph.D.
    Dana-Farber Cancer Institute, Boston, MA USA
  Fusobacterium in the Oral Cavity and Its Signaling Potential
    Sarah Kuebne, Ph.D.
    University of Birmingham, Birmingham, United Kingdom
  Oral Bacteria and CRC: What is Their Role?
    Julia Drews, Ph.D.
    Johns Hopkins University, Baltimore, MD USA
  Fusobacterium nucleatum and Adverse Pregnancy Outcomes
    Yiping W. Han, Ph.D.
    Columbia University, New York, NY USA

1200-1300 LUNCH / INDUSTRY EXHIBITS
1300-1400 POSTER SESSION I / INDUSTRY EXHIBITS
1400-1520 SESSION XI: DOES THE HUMAN MICROBIOME IMPACT TREATMENT OF NON-INFECTIONOUS DISEASE?
  Convener: Cynthia Sears, M.D.
  The Gut Microbiome Affects the Uptake and Metabolism of Drugs
    Jordan Bisanz, Ph.D.
    University of California, San Francisco, San Francisco, CA USA
  The Contribution of Oral Anaerobes to Hypertension: Is There NO Link?
    Nathan S. Bryan, Ph.D.
    Baylor College of Medicine, Houston, TX USA
  Anaerobes and the Brain: The Role of Commensal Microbiota in Neurologic Disease
    Laura M. Cox, Ph.D.
    Harvard University, Boston, MA USA

1520-1530 BREAK
1530-1630 SESSION XII: TAXONOMY CHANGES AND THE CLINICAL IMPLICATIONS
  Convener: DianeCitron
  Winds of Change: Taxonomic Restructuring of the Clinically Important Clostridia
    Paul A. Lawson, Ph.D.
    University of Oklahoma, Norman, OK USA
  Clinical Implications of Anaerobic Taxonomy Change
    Karen Carroll, M.D.
    Johns Hopkins University, Baltimore, MD USA

1630-1800 SESSION XIII: ORAL PRESENTATIONS III: CLOSTRIDIIOIDES (CLOSTRIDIUM) DIFFICILE — LABORATORY RESEARCH
  Convener: Stuart Johnson, M.D.
  Extracellular Vesicles Produced by Clostridioides difficile
    Leandro A. Lobo, Ph.D.
    Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
  Characterization of Germination Inhibitors Against Clostridium difficile R20291
    Christopher Yip
    University of Nevada, Las Vegas, Las Vegas, NV USA
  Persistence of Clostridium difficile Spores in the Intestinal Epithelium and Its Role in Recurrent Disease
    Daniel Paredez-Sahuja, Ph.D.
    Universidad Andrés Bello, Santiago, Chile
  Microbiota of Mucosal Associated Invariant T Cell Deficient Mice Confer Resistance Against Clostridium difficile Infection
    Ashley D. Smith, Ph.D.
    U.S. Food and Drug Administration, Silver Spring, MD USA
  IL-22 Prevents Clostridium difficile Infection Via Modulation of Microbial Metabolic Activities in the Gut
    Nobuhiko Kamada, Ph.D.
    University of Michigan, Ann Arbor, MI USA
  Obesity-Associated Gut Microbiota Enhances Clostridium difficile Infection in Mice
    Shinsmon Jose, Ph.D.
    University of Cincinnati, Cincinnati, OH USA

1900 RECEPTION / BANQUET / AWARDS
HAVANA ROOM, TROPICANA HOTEL
Thursday, July 12

0700-0800  REGISTRATION / BREAKFAST / EXHIBITS

0800-0900  SESSION XIV: ORAL PRESENTATIONS IV: CLOSTRIDIOIDES (CLOSTRIDIUM) DIFFICILE—CLINICAL TRIALS I

Convener: Glenn Tillotson, Ph.D.

Insights from Fidaxomicin, Bezlotoxumab and Surotomycin Clinical Trials: Looking Beyond the Primary Analyses
Mary Beth Dorr, Ph.D.
Merck & Co., North Wales, PA USA
SYN-004 (Ribaxamase) Prevents Clostridium difficile Infection and Antimicrobial Resistance
John F. Kokai-Kun, Ph.D.
Synthetic Biologics, Inc., Rockville, MD USA
The Microbiota-based Drug RBX2660 is Efficacious and Safe in Patients with Recurrent Clostridium difficile Infections: Results from 2 Controlled Clinical Trials
Dale Gerding, M.D.
Hines, Jr. Veterans Affairs Hospital, Hines, IL USA
Misoprostol Protects Mice Against Clostridium difficile Infection and Accelerates Recovery of Gut Microbial Diversity After Antibiotics
David M. Aronoff, M.D.
Vanderbilt University, Nashville, TN USA

0900-0910  BREAK / INDUSTRY EXHIBITS

0910-1020  SESSION XV: THE “NON-DIFFICILE” CLOSTRIDIA: CURRENT CLINICAL & THERAPEUTIC LANDSCAPE

Convener: Dennis Stevens, M.D.

Enterotoxin-Producing Clostridium perfringens Type A: Molecular Mechanisms and Clinical Syndromes
Bruce McClane, Ph.D.
University of Pittsburgh, Pittsburgh, PA USA
Botulinum Neurotoxin-Encoding Plasmids Can Be Congugatively Transferred to Diverse Clostridial Strain
Eric A. Johnson, Sc.D.
University of Wisconsin, Madison, WI USA
The Identification and Characterization of a Novel Extracellular Metalloproteinase Produced by Clostridium sordellii
Michael J. Aldape, Ph.D.
Veterans Affairs Medical Center, Boise, ID USA
Clostridia, Preterm Neonates and Necrotizing Enterocolitis: New Data
Julio Aires, Ph.D.
Paris Descartes University, Paris, France

1020-1030  BREAK / INDUSTRY EXHIBITS

1030-1200  SESSION XVI: AN UPDATE ON CLOSTRIDIUM DIFFICILE PATHOGENESIS

Convener: David Aronoff, M.D.

An Update on the Mechanisms of Action of the Large C. difficile Toxins
D. Borden Lacy, Ph.D.
Vanderbilt University School of Medicine, Nashville, TN USA

1200-1300  LUNCH / INDUSTRY EXHIBITS

1300-1400  POSTER SESSION II / INDUSTRY EXHIBITS

1400-1515  SESSION XVII: CLOSTRIDIUM DIFFICILE—EVOLVING MANAGEMENT

Convener: Dale N. Gerding, M.D.

New IDSA/SHEA Guidelines for CDI Diagnosis and Treatment
Stuart Johnson, M.D.
Loyola University, Maywood, IL USA
Fecal Microbiota Transplant and Derivatives for CDI
Sabi Khabba, M.B.B.S., M.S.
Mayo Clinic, Rochester, MN USA
Update on Newer Agents for CDI
Dale Gerding, M.D.
Hines, Jr. Veterans Affairs Hospital, Hines, IL USA

1515-1530  BREAK

1530-1645  SESSION XVIII: ORAL PRESENTATION V: CLOSTRIDIUM DIFFICILE—CLINICAL TRIALS II

Convener: Vincent Young, M.D., Ph.D.

Oral Beta-Lactamase Therapy Protects the Gut Microbiome from IV and Oral Antibiotics and Mitigates Propagation of Antibiotic Resistance
Sheila Connelly, Ph.D.
Synthetic Biologics, Rockville, MD USA
Developing Microbiome Rehabilitation Biomarkers for Clostridium difficile Infections: Continued Evaluation of a Prototype Microbiome Health Index
Ken Blount, Ph.D.
Rebiotix, Inc., Roseville, MN USA
Gastrointestinal Tract Microbiome Dynamics following Treatment with SER-109: An Investigational Oral Microbiome Therapeutic to Reduce the Recurrence of Clostridium difficile Infection (CDI)
Christopher B. Ford, Ph.D.
Seres Therapeutics, Inc., Cambridge, MA USA
Ridinilazole (RDZ) for Clostridium difficile Infection (CDI)
Richard J. Wickers, Ph.D.
Summit Therapeutics, Abingdon, Oxfordshire, United Kingdom
How about progress towards the Development of a Prophylactic C. difficile Vaccine
Annalisa Anderson, Ph.D.
Pfizer, Inc., New York, NY USA

1645-1700  CLOSING COMMENTS

1700  CONGRESS CLOSES